Marathon Money Podcast Interview

GNPX 12.03.2024

Full Press ReleaseSEC FilingsOur GNPX Tweets

About Gravity Analytica

Recent News

  • 01.23.2025 - Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
  • 01.06.2025 - Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
  • 12.16.2024 - Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Recent Filings

  • 01.23.2025 - 8-K Current report
  • 01.15.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 01.13.2025 - EX-99.1 EX-99.1
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com